ALK and non-small cell lung carcinoma: The pan-immune-inflammation value, which is based on peripheral blood cell counts, was recently used in a retrospective study for predicting the progression-free- and overall survival of ALK + NSCLC patients undergoing first-line ALK TKI therapy [51].